Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study
Authors:
Open Access
- 19 February 2025
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-14
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are closely related to pulmonary hypertension, but the role of IR in patients with CTEPH remains unexplored. In this study, we investigated the relationship between four insulin resistance indices and disease severity, hemodynamic parameters, and adverse outcomes in patients with CTEPH. We conducted a multicenter, retrospective cohort study involving 516 patients diagnosed with CTEPH between January 2013 and December 2022. The metabolic score for IR (METS-IR), triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, triglyceride and glucose (TyG) index, and triglyceride-glucose-body mass (TyG-BMI) index were used to quantify IR levels in patients with CTEPH. The primary endpoint events were clinical worsening. Multivariable Cox regression, restricted cubic splines, and receiver operating characteristic analyses were used to evaluate the predictive value of surrogates for IR. Compared with in low to intermediate-low risk patients, the METS-IR (36.2 ± 6.7 vs. 37.7 ± 8.7, p = 0.038) and TyG-BMI index (204.0 ± 36.2 vs. 212.6 ± 46.5, p = 0.022) were significantly increased in high to intermediate-high risk patients. METS-IR correlated with markers of disease severity, such as World Health Organization functional class, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide levels. During a mean of 2.5 years’ follow-up, 110 participants experienced all-cause death or worsening condition. METS-IR independently predicted clinical worsening (hazard ratio: 1.27; 95% confidence interval 1.06–1.53 per 1.0-standard deviation increment, p = 0.009) after fully adjusting for covariates. Adding METS-IR to the COMPERA 2.0 risk score significantly improved its predictive ability, reclassification and discrimination ability. METS-IR is an independent predictor of clinical worsening in patients with CTEPH. It offers a convenient marker for assessing disease severity and long-term outcomes in clinical risk assessment.Keywords
This publication has 44 references indexed in Scilit:
- Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetesThe Lancet Diabetes & Endocrinology, 2024
- Impact of Preoperative Body Mass Index on Long-Term Survival and Functional Outcomes After Pulmonary Endarterectomy: Results from the UK National CohortThe Journal of Heart and Lung Transplantation, 2024
- Evaluation and Management of Chronic Thromboembolic Pulmonary HypertensionChest, 2023
- Prognostic Significance of Insulin Resistance in Pulmonary HypertensionESC Heart Failure, 2021
- TG/HDL-C ratio and visceral adiposity index may be useful in assessment of insulin resistance in adults with type 1 diabetes in clinical practiceJournal of Clinical Lipidology, 2018
- Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonarRevista Espanola de Cardiologia, 2016
- Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary contextThe Journal of Nutritional Biochemistry, 2013
- Insulin Resistance and Cardiovascular Risk: New Insights From Molecular and Cellular BiologyTrends in Cardiovascular Medicine, 2006
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- ATROPINE SUPPRESSION TEST FOR PANCREATIC POLYPEPTIDEThe Lancet, 1978